STAR.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 12:59):

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally...

Stats
Šios dienos apimtis	150 683
Vidutinė apimtis	523 607
Rinkos kapitalizacija	80.57B
EPS	INR0 ( 2024-01-29 )
Kita pelno data	( INR0 ) 2024-05-23
Last Dividend	INR1.500 ( 2023-08-04 )
Next Dividend	INR0 ( N/A )
P/E	-52.22
ATR14	INR1.197 (0.14%)

Tūris Koreliacija

Ilgas: -0.33 (neutral)

Trumpas: -0.68 (moderate negative)

Signal:(44.595) Neutral

Strides Pharma Science Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Strides Pharma Science Koreliacija - Valiuta/Žaliavos

-0.12
( neutral )

-0.15
( neutral )

0.06
( neutral )

0.15
( neutral )

0.03
( neutral )

-0.30
( neutral )

Strides Pharma Science Finansinės ataskaitos

Annual	2022
Pajamos:	INR36.88B
Bruto pelnas:	INR20.62B (55.89 %)
EPS:	INR-25.63

FY	2022
Pajamos:	INR36.88B
Bruto pelnas:	INR20.62B (55.89 %)
EPS:	INR-25.63

FY	2022
Pajamos:	INR30.22B
Bruto pelnas:	INR14.39B (47.61 %)
EPS:	INR-52.84

FY	2021
Pajamos:	INR32.51B
Bruto pelnas:	INR18.42B (56.67 %)
EPS:	INR29.96

Financial Reports:

No articles found.

Strides Pharma Science Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR1.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Strides Pharma Science Dividend Information - No Dividend Player

Dividend Sustainability Score: 0.216 - low (50.00%) | Divividend Growth Potential Score: 1.260 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR1.500	2010-05-21
Last Dividend	INR1.500	2023-08-04
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR651.50	--
Avg. Dividend % Per Year	0.19%	--
Score	0.96	--
Div. Sustainability Score	0.216
Div.Growth Potential Score	1.260
Div. Directional Score	0.738	--

Next Divdend (Est)
(2024-05-08)

INR0 Estimate 3.16 %

Dividend Stability

0.25 Very Poor

Dividend Score

0.96

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR2.00	0.36%
2019	INR15.00	3.22%
2020	INR2.00	0.55%
2021	INR2.50	0.28%
2022	INR0	0.00%
2023	INR1.500	0.42%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TATACONSUM.NS	Dividend Junior	2023-05-19	Annually	26	0.60%
NIPPOBATRY.NS	Dividend Junior	2023-09-20	Annually	23	1.06%
INDIANB.NS	Dividend Junior	2023-06-12	Annually	18	1.99%
CIPLA.NS	Dividend Junior	2023-07-20	Annually	28	0.41%
SANGHVIMOV.NS	Dividend Junior	2023-08-04	Sporadic	18	0.41%
M&MFIN.NS	Dividend Junior	2023-07-20	Annually	19	1.20%
GLOBUSSPR.NS	Dividend Junior	2023-07-14	Sporadic	15	0.36%
ASTEC.NS	No Dividend Player	2023-07-20	Annually	15	0.08%
TIPSINDLTD.NS	Dividend Junior	2023-08-03	Annually	17	0.03%
PEL.NS	Dividend Junior	2023-06-16	Annually	29	1.59%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0259	1.500	-0.519	-0.778	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.0487	1.500	-1.652	-2.48	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	1.132	1.000	-0.692	-0.692	[3 - 30]
operatingCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.589	1.000	3.52	3.52	[0.2 - 0.8]
operatingProfitMarginTTM	0.0901	1.000	-0.198	-0.198	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				0.216

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-78.17	1.000	-8.00	0	[1 - 100]
returnOnEquityTTM	-0.0487	2.50	-1.062	-2.48	[0.1 - 1.5]
freeCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.171	1.500	5.72	0	[0 - 0.4]
operatingCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0868	1.000	-0.330	0	[0.1 - 0.5]
Total Score				1.260

Strides Pharma Science

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.